Neoadjuvant checkpoint blockade was previously shown to eliminate the need for surgery in a high proportion of patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer. A study published in the The New England Journal of Medicine investigated whether this approach can be extended to all early-stage dMMR solid tumors, regardless of tumor site.
